Efficacy comparison between Titanium nitric-oxide biological active stent and sirolimus-eluting stent in clinical practice
AIM: To compare the efficacy of Titanium nitric-oxide biological active stents (Titan2-BAS) in clinical practice of coronary revascularization compared with sirolimus-eluting stent (SES).METHODS:A total of 141 patients with coronary artery diseases were enrolled. Based on the different stents, 87 patients were enrolled in group A treated with Titanium nitric-oxide biological active stent and other 54 patients enrolled in group B treated with sirolimus-eluting stents. All the stents were implanted through either radial or ulnar artery approach. Patients in group A were administered with aspirin and clopidogrel for 1 to 3 months, while patients in group B for at least 12 months. The stent deliver-y success rate, incidence of early in-stent thrombosis and MACE (death, acute myocardial infarction, and target vessel revascularization) in follow-up were analyzed in both groups. RESULTS: ①The reference vessel diameter is (3. 1 ±0. 4) mm and lesion length is (24 ±3) mm in group A, while it is (3.0 ±0.5) mm and (22 ±4) mm long respectively in group B. There is no significant difference between the 2 groups (P > 0.05 ). ②In group A, 168 Titan2-BAS were implanted in 147 lesions with stenosis > 75% , 1 stent failed to cross the lesion, the delivery success rate is 99. 3%. In group B, 94 units of SES were implanted in 86 lesions, the delivery success rate is 100%. There is no significant difference between the 2 groups ( P > 0. 05 ).③The follow-up period was from 1 to 17 months, with an average of 5. 8 months. No death case found in both groups. There is no acute or late in-stent thrombosis in group A. One patient in group B was found in-stent thrombosis 2 d after the procedure. One patient underwent revascularization 3 months after the procedure in group A, while no revascularization in group B. In summary, there was no significant difference on MACE between the 2 groups (P >0.05).CONCLUSION: The present data suggest that Titan2-BAS is comparable with SES in short-term and long-term efficacy in coronary revascularization. Compared to SES, Titan2-BAS did not show an increase in MACE.
coronary revascularizationtitanium nitric-oxide biological active stentsirolimus-eluting stent
NETL
NSTL
万方数据
维普
